The significant health implications necessitate the development of alternative therapeutic strategies. These strategies could mitigate opioid-induced adverse effects while retaining their analgesic efficacy. Our research focuses on identifying inhibitors of the Kainate (Gluk-1a) Glutamate Receptor, aiming to diminish dopamine production in the Nucleus Accumbens, thus offering a novel approach to address this pressing healthcare challenge.